Eli Lilly (NYSE:LLY) and development partner Boehringer Ingelheim announce that the FDA has designated type 2 diabetes med Jardiance (empagliflozin) for Fast Track review for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.
The companies are currently assessing the SGLT2 inhibitor for the indication in two large-scale Phase 3 studies, EMPEROR-Reduced and EMPEROR-Preserved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.